US-based biopharmaceutical firm Aduro Biotech has started dosing patients in a Phase I/II clinical trial of BION-1301 to treat relapsed or refractory multiple myeloma in adults.

BION-1301 is a humanised anti-a proliferation-inducing ligand (APRIL) antibody that has demonstrated the ability to destroy malignant cells and minimise therapy resistance in disease models.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The multi-centre, open-label Phase I/II trial is designed to assess the safety and activity of BION-1301 in subjects who progressed following a minimum of three previous systemic therapies with immunomodulatory drugs (IMiDs), proteasome inhibitors, chemotherapies or monoclonal antibodies.

Aduro Biotech chief medical officer Natalie Sacks said: “Neutralising APRIL is a differentiated approach in the treatment of multiple myeloma, and it has been shown to inhibit tumour growth and overcome drug-resistance in preclinical studies.

“It has been shown to inhibit tumour growth and overcome drug-resistance in preclinical studies.”

“BION-1301 is our wholly owned novel antibody that has been shown in non-clinical studies to fully block the APRIL-induced signalling cascade at a critical juncture, and we are eager to further characterise its potential activity in the clinic.”

The trial’s Phase I portion is designed to investigate the safety, pharmacokinetics, and pharmacodynamics of increasing doses of BION-1301 given once every two weeks in a 28-day cycle.

Determination of the recommended Phase II dose in the first part will be followed by the initiation of the Phase II portion to evaluate the safety and preliminary activity of the selected dose.

The primary activity endpoint of the second part is objective response rate.